ARTICLE | Financial News

Renal disease play Tricida raises $55M

July 25, 2016 7:00 AM UTC

Tricida Inc. (South San Francisco, Calif.) raised $55 million in a series C round led by new investor Longitude Capital. New investor Vivo Capital also participated, as did existing investors OrbiMed, Sibling Capital Ventures and Limulus Venture Partners.

This year, Tricida expects to complete and report data from a Phase I/II study of lead compound TRC101 in patients with chronic kidney disease (CKD) and metabolic acidosis. The non-absorbed compound is designed to treat electrolyte imbalances in CKD patients. The company declined to disclose TRC101's mechanism. ...